Wells Fargo’s Caris Life Sciences CAI Stock Holding History

Wells Fargo’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-113,500	Closed	-$3.06M	–	7527
2025 Q4	$3.06M	Buy	+113,500	New	+$3.2M	﹤0.01%	3102

Other funds holding CAI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHWEPV

J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM

SSP

Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Wells Fargo's CAI Position: Q1 2026 in Review

Wells Fargo increased its Caris Life Sciences (CAI) stake by 92% in Q1 2026, buying an estimated $180K and bringing the position to 17,250 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #4431.

Wells Fargo first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

Wells Fargo held 17,250 shares of Caris Life Sciences worth $308K as of Q1 2026.
Wells Fargo bought 8,255 Caris Life Sciences shares in Q1 2026, an estimated $180K.
Caris Life Sciences made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4431 holding.
Wells Fargo first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.